GETTING STARTED

Zemaira CareZ is your single-source contact for all things Zemaira.

Full support for patients and physicians

Initiating Zemaira therapy is easy. CareZ, a comprehensive support program, reduces the administrative burden on your practice by managing most of your patient’s product access and financial issues. Zemaira CareZ, pronounced “cares,” acts quickly to ensure your patient receives therapy and support regardless of their financial situation or insurance coverage.

  • Referral is processed and patient contacted within 24 hours.
  • Benefits investigation and pharmacy selected within 72 hours.
  • Ongoing support is provided to both physician and patient.

Starting your patients on Zemaira

All-in-one Zemaira referral

The Zemaira referral form not only gets your patient started on therapy, but also allows quick enrollment options for Zemaira CareZ and the Zemaira QuickAccessSM program, if eligible.

The Zemaira QuickAccess program provides your patient with instant access to therapy.* Once eligibility is verified by a CareZ Coordinator:

  • Patient may receive up to 4 weeks of Zemaira at no cost.
  • Patient may receive up to $3000 in co-pay assistance for the first 12 months.

*The program cannot be used with any other rebate/coupon, free trial, or similar offer. Co-pay assistance under the program is nontransferable. The program only applies in the United States and does not apply where prohibited by law, taxed, or restricted. CSL Behring reserves the right to rescind, revoke, or amend the program at any time without notice. Additional program restrictions may apply.

Confirmation of eligibility and coordination of services with specialty pharmacy may take up to 1 week to complete before patient’s first scheduled infusion. The Zemaira QuickAccess program is only available to new patients diagnosed with Alpha-1. Patients must be 18 years or older, US residents, and insured in the US. Patients covered by state- or federally funded programs, such as Medicare, Medicaid, and Veterans Health Insurance, are NOT eligible.

Patients may experience a gap in coverage between the Zemaira QuickAccess program trial period (up to 4 weeks) ending and their insurance coverage starting. In addition, depending on individual insurance plans, there is a risk that some patients may never start on the commercial product after the trial period.

Sample program

We are pleased to provide your Alpha-1 patient with the option of trying Zemaira for up to 4 weeks.

  • Help your newly diagnosed Alpha-1 patient get comfortable with therapy quickly.
  • Allow your existing patient to try Zemaira before making a switch from his or her current therapy.

Sample product is shipped to your office or a designated healthcare facility. Our specialty pharmacy partners provide the nursing services and supplies needed for the sample program.

Affording Zemaira

Zemaira CareZ connects patients to financial support with programs that are designed to help. A CareZ Coordinator can help patients who:

  • Have a high co-pay, co-insurance, or other out-of pocket costs related to paying for their Zemaira.
  • Are experiencing a gap in their medical insurance coverage or their healthcare plan has turned down paying for their Zemaira prescription.
  • Have no medical insurance or prescription drug coverage, or are underinsured.

Connecting with Alphas for disease management

AlphaNet Coordinators* are also living with Alpha-1 and being treated with Zemaira. An AlphaNet Coordinator can be your patient’s mentor as he or she learns to live with Alpha-1 by:

  • Checking in regularly (usually once a month) to help your patient stay connected to assistance.
  • Providing experience-based, nontherapeutic advice and emotional support.
  • Answering your patient’s questions about his or her condition or treatments.
  • Encouraging lifestyle changes and improvements your patient has initiated to improve his or her overall wellness.

*AlphaNet Coordinators are neither healthcare professionals nor medical experts. Their assistance does not constitute professional guidance, therapy, or psychological counseling. Patients should always contact their physician with medical questions. For their time and expenses, AlphaNet Coordinators are compensated by AlphaNet, Inc., an independent, not-for-profit, 501(c)(3) health management organization.

Maintaining health

Zemaira CareZ provides information and opportunities to help patients adopt a healthier lifestyle.


Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. No clinical data are available demonstrating the effect of augmentation therapy with Zemaira or any A1-PI product on the progression of emphysema in A1-PI deficiency.

Zemaira is not indicated for lung disease patients in whom severe A1-PI deficiency has not been established.

Zemaira is contraindicated in patients with a history of severe systemic reactions to the product or to A1-PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, Zemaira is also contraindicated in immunoglobulin A-deficient patients with antibodies against IgA.

Use caution in administering Zemaira to patients who have experienced anaphylaxis or severe systemic reactions to another A1-PI product. Patients with selective or severe IgA deficiency can develop antibodies to IgA and are at greater risk of such reactions. If anaphylactic or severe anaphylactoid reactions occur during infusion, discontinue immediately.

In pre-licensure clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, asthenia, increased cough, fever, injection-site hemorrhage, rhinitis, sore throat, and vasodilation.

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.
Zemaira QuickAccessSM is a service mark of CSL Behring LLC.

© 2017 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015